AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 92 min read$ABBV

AbbVie (ABBV) Outgrew Humira’s Collapse. Is its Forward P/E Fair for What Comes Next?

AbbVie (ABBV) reported Q3 revenue of $16.99B, up 10.2%, despite a 35.9% drop in Humira sales to $756M. Growth was driven by Skyrizi ($5.505B, +24.4%) and Rinvoq ($2.525B, +24.5%). Adjusted EPS rose 22.9% to $3.65. The company acquired Apogee Therapeutics for $10.9B to bolster its immunology pipeline. Management guided full-year adjusted EPS to $13.87-$14.07.

Original reporting
finance.yahoo.com
Published Oct 9, 2026, 1:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 1:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AbbVie (ABBV) Outgrew Humira’s Collapse. Is its Forward P/E Fair for What Comes Next? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ABBVBullishMed
01

Why it matters

The earnings beat and forward guidance suggest a positive re‑rating for AbbVie, while the sizable acquisition underscores a strategic bet on future immunology pipelines.

02

Market read

Strong earnings and forward guidance make ABBV a candidate for short‑term upside, with sector ripple effects in biotech.

03

What to watch

The $10.9B cash acquisition of Apogee adds execution risk and may dilute near‑term earnings if integration costs rise.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

AbbVie reported its quarterly results, highlighting a 35.9% drop in Humira sales but offset by strong growth in its newer immunology drugs Skyrizi and Rinvoq, plus a recent $10.9B acquisition of Apogee Therapeutics.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

Quarterly earnings released with revenue $16.99B (+10.2%) and adjusted EPS $3.65 (+22.9%); full-year adjusted EPS guidance $13.87‑$14.07.

Expected impact

potential upside as market prices in strong guidance and growth in immunology franchise

Evidence & confidence

Revenue beat, double‑digit EPS growth and forward‑looking guidance indicate improved profitability and growth trajectory.

Market effects

Sector

Immunology and biotech peers may see renewed investor interest as AbbVie's successors to Humira demonstrate strong growth.

Regional

U.S. large‑cap pharma sector could receive a modest lift.

Global

Limited to pharma/biotech investors; no broad macro effect.

Counterpoint

What could challenge this read

If the market has already priced in the guidance, the stock may face limited upside and could be vulnerable to execution risk on new acquisitions.

Key entities

  • company
    AbbVie

    U.S. pharmaceutical company (ticker ABBV) reporting earnings and guidance.

  • company
    Apogee Therapeutics

    Biotech acquired by AbbVie for $10.9B.

Read at source← All news

Related articles

OCT 8
$ABBVMed

AbbVie gets two FDA breakthrough designations for Temab-A

AbbVie Inc. (ABBV) announced on Oct. 7 that the FDA granted Breakthrough Therapy designations for its investigational drug Temab-A in colorectal and non-small cell lung cancer. The designations are based on preliminary clinical evidence from the M21-404 study, but detailed efficacy and safety data were not provided. Temab-A remains unapproved, and marketing applications are pending. AbbVie is eligible for intensive FDA guidance and Fast Track features.

mugglehead.com3 min